Mcp (Metoclopramide)

Metoclopramide blocks dopamine D2 receptors in the brain’s chemoreceptor trigger zone, reducing the urge to vomit, and it stimulates gastrointestinal motility by enhancing coordinated muscle contractions, which speeds gastric emptying and supports lower oesophageal sphincter tone.

The specific dose of Mcp is determined by the prescribing clinician based on the patient’s condition, age, renal function and response to therapy. Dosage regimens are individualized and should follow local prescribing guidelines.

Safety data for metoclopramide in pregnancy are limited, and the drug should only be used when the potential benefit justifies any potential risk to the fetus. It is excreted in breast milk, so caution is advised for nursing mothers, and a healthcare professional should evaluate the risk‑benefit balance.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Mcp (metoclopramide) differs from other antiemetics such as ondansetron, which primarily blocks serotonin receptors, by targeting dopamine D2 receptors and also enhancing gastric motility. This dual action makes it useful for both nausea control and gastroparesis, whereas some alternatives lack the pro‑kinetic effect.

Mcp should be stored at temperatures below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Maintaining these conditions helps preserve the tablet’s stability and potency throughout its shelf life.

Mcp is taken orally, usually with a glass of water. The tablet should be swallowed whole and not chewed or crushed, unless a prescriber provides specific instructions for a different administration method.

The most serious risks include extrapyramidal reactions such as dystonia or tardive dyskinesia, neuroleptic malignant syndrome, severe depression or suicidal ideation, and rare allergic reactions like anaphylaxis. Patients should be monitored closely for any of these symptoms, especially during early treatment.

Mcp should be avoided in individuals with known hypersensitivity to metoclopramide, in patients with pheochromocytoma, in those taking monoamine oxidase inhibitors, and in patients with a history of severe extrapyramidal disorders. Caution is also advised for patients with significant renal impairment.